drugset / Trial / NCT04013217
Evaluate Eribulin ORA in Subjects With Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is a nonrandomized, open-label, dosed escalation, safety activity, and PK study to determine the MTD and optimal dosing regimen of Eribulin ORA.
Timeline
- Start
- 2019-07-29
- Primary completion
- 2022-03-02
- Completion
- 2022-03-02
Outcome
Outcome not reported
Stopped (Business): “Sponsor Decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eribulin | Small molecule | — | Oral |
| Subject | HM30181A-UK | Unknown | — | — |